A phase I trial of ZGN 1061 in patients with obesity
Phase of Trial: Phase I
Latest Information Update: 15 Sep 2017
At a glance
- Drugs ZGN 1061 (Primary)
- Indications Obesity
- Focus Adverse reactions; First in man
- Sponsors Zafgen
- 15 Sep 2017 Results presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
- 12 Sep 2017 Data from this trial presented at the 2017 53rd Annual Meeting of the European Association for the Study of Diabetes in Lisbon, Portugal, according to a Zafgen media release.
- 10 Jun 2017 Results published in a Zafgen media release.